Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21173306 | 0.91 | PREP (0.39) | PREPELANECHRM2CHRM1CHRM3 | |
| SCHEMBL18828778 | 0.74 | PREP (0.38) | PREPCHRM2CHRM1CHRM3 | |
| SCHEMBL21173305 | 0.74 | PREP (0.36) | PREP | |
| SCHEMBL24896835 | 0.70 | — | — | |
| SCHEMBL20639384 | 0.68 | TDP1 (0.39) | PREPCHRM2CHRM1CHRM3 | |
| SCHEMBL18943173 | 0.68 | TDP1 (0.39) | PREPCHRM2CHRM1CHRM3 | |
| SCHEMBL887944 | 0.68 | PREP (0.67) | PREPELANECHRM2CHRM1CHRM3 | |
| SCHEMBL15934761 | 0.68 | PREP (0.67) | PREPELANECHRM2CHRM1CHRM3 | |
| SCHEMBL2371269 | 0.68 | PREP (0.67) | PREPELANECHRM2CHRM1CHRM3 | |
| SCHEMBL27101241 | 0.68 | PREP (0.67) | PREPELANECHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | PREP 15/4885ELANE 109/4885CHRM2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.